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Genetic influences on viral-induced cytokine responses in the
lung
Jessica L. Forbester 1,2 and Ian R. Humphreys1
Infection with respiratory viruses such as influenza, respiratory syncytial virus and coronavirus provides a difficult immunological
challenge for the host, where a balance must be established between controlling viral replication and limiting damage to the
delicate lung structure. Although the genetic architecture of host responses to respiratory viral infections is not yet understood, it is
clear there is underlying heritability that influences pathogenesis. Immune control of virus replication is essential in respiratory
infections, but overt activation can enhance inflammation and disease severity. Cytokines initiate antiviral immune responses but
are implicated in viral pathogenesis. Here, we discuss how host genetic variation may influence cytokine responses to respiratory
viral infections and, based on our current understanding of the role that cytokines play in viral pathogenesis, how this may
influence disease severity. We also discuss how induced pluripotent stem cells may be utilised to probe the mechanistic
implications of allelic variation in genes in virus-induced inflammatory responses. Ultimately, this could help to design better
immune modulators, stratify high risk patients and tailor anti-inflammatory treatments, potentially expanding the ability to treat
respiratory virus outbreaks in the future.
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IMPACT OF INFLAMMATION ON PULMONARY VIRAL
INFECTIONS
The primary role of the lung is gas exchange and oxygen delivery,
which are fundamental processes for host survival, but also leave
the lung vulnerable to pathogens due to constant exposure to the
external environment.1 Therefore, the lung provides a difficult
immunological challenge for the host, where a balance must be
maintained between defending against any would-be microbial
invaders, whilst limiting damage to lung cells and the delicate
structure. Infection with respiratory pathogens can lead to
obstruction of the airways, loss of alveolar structure and
degradation of the critical extracellular matrix; this damage can
result in severely compromised lung function, potentially resulting
in death of the host.2,3
To respond to respiratory pathogens, the host must initiate an
immune response. Rapidly after infection, pathogen associated
molecular patterns (PAMPs) are detected by pattern recognition
receptors (PRRs), activating transcription factors (TFs), such as
interferon regulatory factors (IRFs) and NFκB, which subsequently
induce the upregulation of sets of genes including cytokines and
interferons (IFNs). IFNs induce the upregulation of IFN-stimulated
genes, ISGs, whose products can directly restrict pathogens.
Cytokines and chemokines regulate the second arm of defence,
recruiting and coordinating specific subsets of leucocytes. Increas-
ing innate resistance to a pathogen and increasing tolerance to the
resultant infection are two strategies of host defence; the severe
lung inflammation associated with some respiratory infections is a
difficult challenge for the immune system. Susceptibility occurs if a
host is unable to reduce the pathogen burden or tolerate the
negative consequences of the immune response.4,5
VIRAL RESPIRATORY PATHOGENS
The predominant viral pathogens causing lower respiratory tract
infections (LRTI) in humans are respiratory syncytial virus (RSV),
enteroviruses such as human rhinoviruses, adenoviruses, human
metapneumovirus, influenza and parainfluenza viruses.6 In addi-
tion, novel coronaviruses (CoVs) derived from animal populations
have infected humans in recent years, including SARS-CoV-2,
which also target the lower respiratory tract.7 Furthermore,
seasonal CoVs can cause acute LRTI in infants and immunocom-
promised patients.8,9 Herein, we will briefly focus on the
inflammatory responses induced by the more severe respiratory
viral infections influenza, RSV and coronavirus, which are currently
the respiratory viral pathogens that pose the most significant
challenge to global public health.10 We acknowledge the
importance of bacterial co-infection, particularly with respect to
influenza infection. However, due to space restrictions, we will
focus on primary viral infections.
Influenza
Influenza is one of the most well-studied respiratory viruses. It
occurs in two forms: seasonal (epidemic) influenza caused by
Influenza A and B viruses (IAV), and sporadic pandemics caused by
IAV.11 In the majority of seasonal influenza infections, inflamma-
tion is usually limited to the upper respiratory tract, and symptoms
are fairly mild.12 However, during severe IAV infections, often
associated with pandemic strains, the virus can reach the alveolar
epithelium in the lower respiratory tract, potentially causing
severe tissue damage, affecting gas exchange and sometimes
leading to respiratory dysfunction or acute respiratory distress
syndrome (ARDS).13
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In IAV-induced ARDS most of the lung pathology is associated
with the release of cytokines and other pro-inflammatory
mediators.14 Elevated serum levels of pro-inflammatory cytokines
and chemokines, including IL-1β, IL-6, TNF-α, IL-8, MCP-1, MIP-1β
and IP-10, have been identified as markers of severity in acute
lung injury during infection with IAV pandemic H1N1/09.15–18
Furthermore, in humans, observations in H5N1-infected indivi-
duals suggest that high viral loads and the resulting intense
inflammatory responses are central to influenza H5N1 pathogen-
esis, and that the focus of clinical management of this virus should
consider preventing this intense cytokine response.19 In young
‘healthy’ adults, IAV pH1N1/09 induces a TNF-αhi M1-like mono-
cyte response that correlated with disease severity.20
In vivo models have been used to dissect roles for cytokines in
IAV-associated pathogenesis. Despite the lack of susceptibility to
many human IAV strains, mice are often used as an IAV model due
to their practicality and versatility as an experimental system. Most
research uses inbred C57BL/6 or BALB/C mice in conjunction with
lab adapted A/Puerto Rico/8/1934 (H1N1) [PR/8] or A/WSN/1933
(H1N1) [WSN] influenza viruses. These tend to be more pathogenic
in mice than humans; replicating and causing damage predomi-
nantly in the lower respiratory tract, causing rapid mortality, with
severe lung inflammation associated with an influx of neutrophils
and macrophages.21 Highly pathogenic viruses of the
H5N1 subtype, certain H7 subtype viruses and 2009 H1N1
pandemic strains do not need to be adapted for murine infection.
X31, a reassortment virus with HA and NA genes of A/Hong Kong/
1/1968 (H3N2) in the PR8 background, generates a milder
infection in mice, and does not result in the rapid mortality
observed with PR/8 and WSN.22
The type I IFNs, IFN-α and IFN-β, are expressed early in IAV
infection and establish feedback loops through IFN α/β receptor
signalling, sustaining the production of other pro-inflammatory
cytokines such as IL-6, TNF-α and IL-1β.23 Type I IFNs also induce
factors that limit virus replication, such as members of the
interferon-induced transmembrane (IFITM) and tripartite motif
families.24 Although type I IFN production is important for
initiating antiviral responses, high type I IFN production during
infection can drive exacerbated pathology by amplifying pro-
inflammatory responses.2 In studies using different mouse and IAV
strains, there was a direct correlation between high IFNα/β levels
and morbidity and mortality, linked to high levels of inflammatory
cytokines and chemoattractants and subsequent pulmonary
cellular inflammation, including increased inflammatory monocyte
tumour necrosis factor-related apoptosis-inducing ligand expres-
sion and death receptor 5 expression on epithelia, mediating lung
tissue damage.25,26 In macaques, highly pathogenic avian
influenza strain H5N1 induced sustained expression of innate,
inflammatory and type I IFN genes, as well as complement
pathway components, genes encoding antiviral proteins such as
IFIT1 and IFIT2, and chemokines. This corresponded with
apoptosis of DCs in the lung and the draining lymph node early
in infection, and severe lung pathology. This was in contrast to
infection with H1N1 strains, which induced less severe clinical
disease in this model, where expression of type I IFN and
inflammatory cytokines was initially high but dissipates rapidly,27
in accordance with data from murine models demonstrating that
sustained IFNα/β production induces pathology (28). In a similar
macaque study, the severity of disease after infection with the
1918 pandemic strain of H1N1 influenza is also associated with
severe pulmonary pathology, correlated with upregulation of
inflammatory and cell death genes, with induction of macrophage
and neutrophil infiltration resulting in acute lung inflammation
and dysregulation of antiviral responses.28 Type III IFNs (IFN-λs),
also produced very early after infection, inhibit influenza spread
from the upper respiratory tract to the lower respiratory tract in
mice.29 Murine models indicate that type III IFNs are important for
controlling influenza replication in the lung mucosa, with IFNα/β-
signalling essential for controlling systemic immune responses.
When mice are challenged with strains of IAV that can replicate
outside the respiratory tract, Ifnar1−/− and STAT1−/− animals
exhibit high viral titres in the liver, spleen and brain, in contrast to
WT mice. However, with viruses that replicate solely with the
respiratory tract, IFN-λ appears sufficient for viral control.29,30
Glucocorticoids, which suppress production of cytokines, are
not protective in IAV infection in mice, suggesting that targeting
the host inflammatory response may be ineffective.31 Indeed,
aside from data from dexamethasone treatment of COVID-19 (see
below), little evidence from clinical studies suggests that
glucocorticoids ameliorate symptoms of respiratory viral
infections.32,33 Importantly, however, cytokines such as IL-6 and
TNF-α have pleiotropic roles in IAV infection; IL-6 is required for
neutrophil survival in the lung34 and antiviral T-cell develop-
ment.35 One study reported that TNF-α induces RIG-I expression,
which enhances antiviral cytokine production,36 and another
demonstrated direct inhibition of viral replication in lung epithelial
cells,37 although both of these studies were carried out in vitro
using cell lines. In vivo, TNF-α neutralisation ameliorates IAV-
induced pulmonary inflammation and illness severity without
impacting host control of IAV replication38 and TNF-α deficient
mice exhibit reduced IAV-induced lung pathology.39 Triple mutant
mice deficient in TNF-R1, TNF-R2 and IL-1-R1 display reduced lung
inflammation and delayed onset of death when challenged with
highly virulent H5N1 IAV (but not less virulent IAV), and this
correlated with reduced pulmonary macrophage and neutrophil
infiltrates.40 IAV-induced TNF-α can induce monocyte migration.41
TNF-α also exhibits pleiotropic functions from induction of cellular
survival, proliferation and cellular suicide,42 demonstrating a broad
array of mechanisms through which TNF-α may drive IAV-induced
lung damage.
Regulatory cytokines can dampen IAV-induced inflammation.
For example, T cell-derived IL-10 ameliorates pulmonary inflam-
mation, lethal lung injury and accelerated death, without
impacting viral clearance,43 although an antagonistic role for IL-
10 in protective anti-IAV immunity has also been described.44,45
The IL-12 family cytokine member IL-27 restricts IAV-induced
weight loss, TH1 and TH17 cell, and neutrophil accumulation
46 and
promotes the development of IAV-induced IL-10+ CD8 T cells.47 IL-
37, a member of the IL-1 family of ligands, acts as a negative
feedback inhibitor of inflammatory cytokines, independently of
anti-inflammatory cytokines such as IL-10.48 Treatment of mice
with IL-37 after influenza infection decreases lung injury and
production of pro-inflammatory cytokines.49
Murine models of IAV infection have also revealed that myeloid
cells can play both protective and immunopathogenic roles
during IAV infection, with inflammatory monocytes and
monocyte-derived DCs identified as driving inflammation and
lung pathology,50,51 with IAV-induced IFNs important in modulat-
ing homoeostatic versus inflammatory functions of monocytic
cells.52 In pathogenic IAV (PR8, H1N1) infection, partial ameliora-
tion of TNF-α-iNOS producing (Tip)-DC responses, which were
elevated in lethal infections, exhibited protective activity, whereas
complete ablation failed to ameliorate disease as tipDCs were
essential for the development of protective CD8+ T-cell
responses.53 Modulation of inflammatory versus regulatory func-
tion of myeloid cells is important in determining outcome of IAV-
associated disease. For example, CD200, expressed by lung
epithelial cells, interacts with CD200R on alveolar macrophages
(AMs), suppressing their inflammatory function and reducing
amplitude and duration of inflammation post-IAV infection.54
RSV
RSV is an important aetiological agent of respiratory infections,
particularly in children. Infections can be limited to the upper
respiratory tract, but in cases associated with greater morbidity
and mortality, RSV can cause LRTI, including pneumonia and
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bronchiolitis.55 Immune responses to RSV have been summarised
in detail elsewhere, with age a major determinant in RSV-related
disease.56 Briefly, in some cases poorly controlled RSV replication
occurs due to a delayed and/or ineffective immune response,
resulting in a high viral load, and has been attributed to disease
development. However, in other cases, an overexuberant immune
response to the virus is observed, resulting in severe lung
inflammation. As observed with IAV, levels of inflammatory
cytokines such as IL-6 and TNF-α,57–59 as well as chemoattractants
such as CCL2,60,61 which recruit inflammatory innate immune cells,
have been found to be elevated in patients, correlating with
disease severity, and are also induced after RSV-challenge in
animal models. Increased cellular infiltrate comprising increased
monocytes, T cells and neutrophils has been described in children
with severe and fatal bronchiolitis.62
The balance of different T-cell subsets is known to correlate with
different disease outcomes in RSV-infected infants. Initially, an
imbalance in TH1/TH2 subsets was thought to explain some of the
differences in clinical severity in RSV-infected individuals. However,
more recently the balance between Treg and TH17 subsets, and
their roles in regulating TH1/TH2 skew and altering RSV disease
pathogenesis, has begun to be elucidated.63 Treg cells have been
shown to play important anti-inflammatory roles during RSV
infection via suppression of pathogenic activated CD4+ and CD8+
T cells and IL-13/GATA3-expressing TH2-type CD4
+ T cells, inhibit-
ing lung eosinophilia.64 Furthermore, IL-10 production by Tregs
dampens T-cell inflammation in the lung,65 and therapeutic
induction of Tregs reduces RSV-induced pulmonary inflammation
without affecting viral clearance.66 γδ T cells promote RSV-induced
inflammation and disease severity in mice67 and these cells
produce IL-17, which plays an important role in neutrophil
recruitment and activation68 and is increased in children with
severe RSV. IL-33, a member of the IL-1 family of cytokines, acts as
an alarmin at barrier sites, and can promote inflammatory diseases
including allergic asthma, rheumatoid arthritis and chronic
inflammation of the gut.69 Age-dependent, rapid IL-33 production,
which correlates with an increase in lung ILC2s, drives TH2 biased
RSV-induced immunopathogenesis.70 Thus, alterations in cytokine
profiles impacts RSV-associated disease outcome.63
As described for IAV, some cytokines play pleotropic roles in
RSV infection. In a case report for two young children who died
suddenly after contracting RSV, early IL-6 was elevated >200-fold
above normal levels.71 However, IL-6 has anti-inflammatory
properties during RSV infection in a murine model via early
induction of IL-27, which promotes regulatory T cell maturation
and restricts TH1-mediated immunopathology in this model,
72 and
can suppress IL-17 production and associated mucous
responses.73 Type I IFN associates with severe RSV-associated
lung inflammatory disease, amplifying pro-inflammatory cytokine
production74 and inducing recruitment of inflammatory mono-
cytes to the lung, which can limit virus replication but, in excess,
also contribute to damage.75 AMs are also responsible for the
recruitment and activation of NK cells after RSV infection,76 with
NK cells playing an important antiviral role, killing infected cells
but also promoting TH1 responses by production of IFN-γ.
77
Coronaviruses
Newly emerging CoVs are becoming one of the greatest global
health challenges of the twenty-first century. In the last 20 years,
there have been three zoonotic outbreaks of beta-CoVs, causing a
range of severe respiratory syndromes in humans. In 2002–2003,
severe acute respiratory syndrome coronavirus (SARS-CoV)
emerged from bat and palm civet populations and infected over
8000 people causing over 800 deaths; in 2012, Middle East
respiratory syndrome coronavirus emerged from dromedary camel
populations and is still endemic in the Middle East; and at the end
of 2019, SARS-CoV-2 emerged from a currently unknown animal
reservoir,78 although it is thought to be of probable bat origin,79 in
Wuhan, China, initiating a global pandemic resulting in hundreds
of thousands of deaths at time of writing.
During the SARS-CoV outbreak, cytokine dysregulation was
associated with disease severity in patients, and was accompanied
by pronounced macrophage infiltration into lungs,80 with TH1-
related cytokine storms observed in some severe clinical
manifestations81,82 accompanied by the accumulation of mono-
cytes, macrophages and neutrophils.82 Fatal SARS also associated
with exacerbated IFN production and persistent expression of
ISGs.83 In a mouse model for SARS-CoV, pulmonary inflammation
associated with complement-mediated lung disease,84 and
elevated chemokines and cytokines driven by inflammatory
monocyte-macrophages resulted in vascular leakage, impaired
virus-specific T cell responses, and ultimately reduced survival.
This was demonstrated to be orchestrated by delayed type I IFN
signalling. Ifnar1−/− mice were protected from lethal infection,
interestingly without exhibiting increased viral load, suggesting
that in SARS type I IFN drives immunopathology.85 Conversely, in
humans, the importance of the type I IFN pathway in protection
against SARS-CoV-2 has been recently highlighted in a study
demonstrating that individuals with loss-of-function variants in
the TLR3- and IRF7-dependent type I IFN signalling pathway are
pre-disposed to life-threatening pneumonia after infection with
SARS-CoV-2.86 Further highlighting the crucial role of type I IFN in
COVID-19 immunity in humans, auto-antibodies against type I IFN,
which were capable of neutralising the ability of type I IFNs to
block SARS-CoV-2 infection in vitro, were associated with severe
life-threatening COVID-19 infection.87
Symptoms in most SARS-CoV-2-infected patients are relatively
mild to moderate, but in ~15% of patients there is progression to
severe pneumonia, and about 5% eventually develop ARDS,
septic shock and/or multiple organ failure.88 The importance of
inflammation in COVID-19 is highlighted by recent data
demonstrating that dexamethasone, a corticosteroid, has been
used in the randomised evaluation of COVID-19 therapy trial,
reducing 28-day mortality among those receiving invasive
mechanical ventilation or oxygen at randomisation.89 Cytokines
associated with secondary haemophagocytic lymphohistiocyto-
sis, a hyperinflammatory syndrome characterised by fulminant
and fatal hypercytokinaemia with multiorgan failure, have been
found to be elevated in COVID-19 fatalities.90 Indeed, high IL-6
and TNF-α,91 and IL-6, IP-10 and IL-1092 have been demonstrated
to predict disease severity in clinical studies. Furthermore, in cell
and animal models of SARS-CoV-2, in conjunction with transcrip-
tional and serum profiling of COVID-19 patients, monocyte-
associated chemokines such as CCL2 and CCL8 were shown to be
elevated, along with neutrophil chemoattractants CXCL2 and
CXCL8.93 As elevated levels of circulating neutrophils have been
observed among COVID-19 patients,94,95 neutrophils may possi-
bly contribute to disease severity. As observed in animal models
of SARS-CoV, there was also delayed expression of type I IFN93
although transcriptomics of BAL fluid from COVID-19 patients has
revealed high ISG expression, together with chemokine-
dominated hypercytokinemia.96 In a mouse model of SARS-
CoV-2, type I IFNs are significant drivers of pathological
responses, enhancing expression of monocyte-recruiting chemo-
kines and recruitment of pro-inflammatory cell types to the
lung.97 With no drugs or vaccines currently available for SARS-
CoV-2, and the evidence from both SARS-CoV and SARS-CoV-2
patients that elevated cytokine expression correlates with
pathology, there is increasing interest in the use of neutralising
monoclonal antibodies targeting inflammatory cytokines and
receptors. Tocilizumab, which targets the IL-6 receptor, has
recently been used in a small clinical trial, where it was reported
to reduce fever and improve respiratory function in 21 patients.
Other potential targets considered include IL-1 and IL-17, as well
as small-molecule inhibitors of signalling components down-
stream of these cytokines.88
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INFLUENCE OF GENETIC VARIATION ON VIRAL-INDUCED
INFLAMMATION
Substantial variation exists in individual outcomes following
exposure to viral pathogens,98 which in part will be influenced
by microbial and environmental factors. Underlying risk factors
including obesity, diabetes, chronic lung disease, cardiovascular
disease, pregnancy, old or young age and being immunocom-
promised also alter disease susceptibility.99 However, early familial
studies indicated that deaths from infectious diseases had a
strong genetic background.100–102 Specifically for respiratory virus
infections, there has been an increase in evidence of a genetic
association between the host and the severity of influenza
infection, with contribution of heritability to fatal outcome clear
in some cases.103 Furthermore, in the current SARS-CoV-2
outbreak, recent data from UK twin studies suggest that
symptoms of COVID-19 may be heritable.104
Life-threatening primary infections often observed in childhood
may more likely result from single-gene inborn errors of
immunity.105,106 Rare, loss-of-function mutations can result in
life-threatening susceptibility to common infections and are due
to deleterious variants in key genes of the immune system. The
contribution of these monogenic disorders to infectious disease
susceptibility has been reviewed elsewhere.105–107 Identification of
these mutations has exposed some of the underlying pathways
essential for viral control in human hosts.6,108 For example, it is
well-characterised that loss-of-function mutations in the type I IFN
pathway result in increased susceptibility to various viral
infections,109,110 although the detrimental effects of loss of type
I IFN signalling can be compensated for by type II/III IFN in some
cases.111 Defective innate cytoplasmic recognition of RNA viruses,
preventing activation of an efficient antiviral IFN response, can be
caused by loss-of-function variants in IFIH1, leading to extreme
susceptibility to common respiratory viruses.6 Patients with
deficiencies in IFN-γ responses, attributed to non-functional or
dysfunctional IFN-γ receptors, have been shown to display
increased susceptibility to viruses, including RSV and parain-
fluenza virus.112 However, it is unlikely that these rare, highly
penetrant, deleterious mutations contribute to the majority of
infectious disease cases, because there is a lack of mendelian
transmission in most cases of infectious disease susceptibility, and
severe deleterious mutations should be rapidly eliminated from
populations.113
Instead, severe infections in adults may result from a more
complex combination of factors, with potential contribution of
inherited (germline) genetic variation. The genetic architecture of
infectious diseases is not yet fully understood. As described by Hill
et al.,113 it is possible that either: most genetic variation is encoded
by relatively common genetic variants that cumulatively account
for most of the genetic variance; that most relevant genetic
variation is encoded by very rare mutations that have almost
complete penetrance, as observed in primary immunodeficiency
disorders; or that there is a predominant role for many individual
rare variants with incomplete penetrance, with these three
theories not necessarily being mutually exclusive. Dissecting the
underlying mechanisms of variable susceptibility to respiratory
viruses may help effective targeting of vaccine therapies, reveal
new therapeutic approaches and, potentially, help contribute to
future clinical risk prediction models.114
The introduction of genome-wide association studies (GWAS)
revolutionised the field of complex disease genetics,115 but very
few GWAS studies have been performed for infectious diseases.116
This is partly due to the very large sample sizes of cases and
controls required from the same population, alongside well-
characterised clinical data sets for each individual. Detection of
specific genetic variants predisposing individuals to certain
infectious diseases is more likely when these variants are
polymorphic and have large effect sizes.113 Therefore, most
studies have relied upon candidate genetic variants based on
biological information pertaining to that specific genetic region,
using targeted single nucleotide polymorphism (SNP)-genotyping
in cases versus controls. As discussed above, disease severity after
infection with respiratory viruses can correlate with increased
expression of host inflammatory mediators, with evidence of de-
coupling of viral load and lung damage in some patients,
suggesting that specific host predisposition could be responsible
for the different magnitudes of inflammatory responses observed
in patients.20,56 Below, we review the host genetic susceptibility
data available for increased susceptibility to respiratory viruses
within the framework of inflammation as introduced in the first
section of this review, with the current known genetic variants
summarised in Fig. 1 and Table 1.
Cytokines and chemokines
Variants in genes encoding cytokines or chemokines, their receptors,
or their promotor regions, have been associated with more severe
infection outcomes for different respiratory viruses. In IAV infections,
the most severe responses are associated with ‘cytokine storms’ or
hypercytokinemia. As previously reviewed,117 SNPs in TNF, CCR5,
IL1A and IL1B are associated with susceptibility and severity of
influenza infections, although the mechanism by which these SNPs
may increase disease susceptibility remains to be fully elucidated. In
accordance with possible anti-inflammatory functions of TNF-α, the
TNF −238 A allele, which has been demonstrated to correlate with
lower TNF transcripts, was overrepresented in IAV pH1N1/09
infected patients in comparison to healthy controls in a Caucasian
population.118 The T allele of rs17561 in IL1A is associated with a
twofold increase in influenza infection risk, suggesting functional
variation in the IL-1A protein in individuals with this genotype,
although this has not been functionally validated.119 CCR5 encodes
the receptor CCR5, which mediates leucocyte chemotaxis in
response to ligands such as RANTES, MIP-1a and MIP-1b. Individuals
who are heterozygotic for the CCR5-Δ32 mutation, which results in a
32 bp deletion in the coding region of the CCR5 gene and partially
reduced receptor expression,120 exhibit more severe IAV disease,121
although this was not replicated in subsequent studies in different
populations.122,123
As reviewed by Kenney et al.124 and Miyari and DeVincenzo,125
there are several common human genetic variants associated with
the development of a more severe RSV infection phenotype,
including in genes encoding cytokines (IL4, IL8, IL10 and IL13) and
their receptors (IL4RA).126–129 In a study in Korean children, the IL4
common haplotype −589T was shown to be overrepresented in
patients with severe disease. This SNP has been demonstrated to
associate with increased transcriptional activity of IL4, suggesting
that the increased TH2 response observed in these patients could
be mediated by IL4 overexpression.127 Similarly, an IL8 haplotype
comprising six SNPs (−251A/+396G/+781T/+1238delA/+1633T/
+2767T) results in increased IL8 transcripts in respiratory epithelial
cells, with this haplotype shown to associate with the severity of
RSV-induced bronchiolitis.130 Despite the observation that very
high levels of IL-6 can act as a biomarker for severe RSV in young
children,71 the IL-6 −174 CC genotype (low-production pheno-
type) is associated with a more severe illness after RSV
infection.131,132 In mice, early IL-6 production is required for IL-
27 production by macrophages and monocytes, driving the local
maturation of Tregs.72 Haplotypes within the IL13–IL4 locus have
been associated with more severe RSV-related disease in
infants.127,133 IL-4 and IL-13 are two cytokines involved in the
type II inflammatory response,134 and excess TH2 responses are
observed in severe RSV disease.133
In accordance with a role for type I IFN in RSV pathogenesis in
mice,74,75 a SNP in IFNA5 was strongly associated with the
development of bronchiolitis, although the specific function of
this SNP is currently undefined.135 In a study genotyping children
hospitalised with RSV infection, children who were heterozygous
at position −592 (CA; rs1800872) in the IL10 gene, which alters IL-
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10 protein level,136 were under-represented in the hospitalised
group, suggesting that altered IL-10 mediated regulation of RSV-
induced immune responses may alter outcome,137 as implied by
data from the murine models.65 Moreover, genetic interactions
between the IL-10 −592 and IL-4Rα −551 polymorphisms were
observed in this human study, suggesting these alleles may
interact, although the mechanism is currently unclear.137
There were few genetic susceptibility studies performed during
the SARS-CoV 2003 outbreak, although in two Chinese cohorts
from Hong Kong and Beijing, RANTES −28 G allele was associated
with disease susceptibility and severity.138 This genotype has
previously been associated with enhanced promotor activity.139
Interestingly, in a recent study in ten terminally ill, critical COVID-
19 patients, blocking of CCR5, the receptor for RANTES, rapidly
reduced plasma IL-6, restored CD4/CD8 T-cell ratios and sig-
nificantly decreased SARS-CoV-2 viraemia, suggesting increased
RANTES could contribute to SARS-CoV-2 disease severity by
driving unchecked inflammation.140
Pattern recognition receptors (PRRs)
PRRs recognise viral PAMPs during respiratory viral infections and
induce pro-inflammatory cytokines and IFNs.141–143 Thus, genetic
variation in PRRs and downstream signalling molecules that alter
their abundance or activity may influence viral pathogenesis.
Polymorphisms in TLR3 associate with increased incidence of
influenza-related pneumonia in children infected with IAV pH1N1/
09, specifically the rs5743313 CT genotype.144 The CC genotype of
this SNP was also associated with higher death outcomes in
influenza-infected Chinese individuals. The exact mechanism of
this SNP is undefined, however it is located in the intronic region
of TLR3 near exon 4, which is the region that encodes the
transmembrane signal transduction domain, so it is potentially
linked to impaired signalling and weakened host immune
response.145 The cytoplasmic sensor RIG-I, encoded by the gene
DDX58, recognises dsRNA and 5′-triphosphates of the negative
ssRNA IAV genome. Two heterozygous variants were identified in
DDX58 in a male Caucasian patient with severe IAV pH1N1/09
infection; SNP rs72710678 in the caspase activation and recruit-
ment (CARD) domain and SNP rs138425677 in the RNA binding
domain. These variants were associated with decreased recogni-
tion function of RIG-I, impaired antiviral responses and increased
pro-inflammatory responses, corresponding with increased
immunopathology.146
In infants hospitalised with RSV, disease severity associated with
a p53-responsive TLR8 SNP. After induction of p53 and incubation
with single-stranded RNA ligands in human primary lymphocytes,
SNP-dependent IL-6 expression, TLR8 expression and p53 binding
were all increased.147 Variation in TLR4 also associates with severe
RSV disease, although this has not been replicated in all cohorts.56
Two SNPs encoding Asp299Gly and Thr399Ile substitutions in the
Fig. 1 Host genes with identified genetic variants associated with altered inflammatory phenotype post-infection with the respiratory
viruses. Response to respiratory viruses requires initiation of an immune response. After viral infection of the lung epithelia, pathogen
associated molecular patterns (PAMPs) are detected by host pattern recognition receptors (PRRs), such as TLRs and cytoplasmic sensors like
RIG-I. This recognition starts a series of signalling cascades within the host cell, involving activation of TFs such as IRF5, IRF7 and AP-1,
resulting in the production of pro-inflammatory cytokines such as IL-6, TNF and IL-1B, and type I IFNs. Cytokines produced by innate immune
cells early post-infection drive several processes such as recruitment of circulating leucocytes, which, in turn, can enhance local cytokine
production at the site of infection and enhance tissue damage; and activate dendritic cells to move to the lymph nodes and activate T cells by
presentation of viral antigen on MHC molecules. Other innate immune cells such as macrophages and DCs also sense PAMPs through PRRs,
again activating TFs and driving cytokine and IFN production. Acting through their receptors, type I IFNs establish an antiviral state in
surrounding non-haematopoietic cells and recruited haematopoietic cells, where activation of TFs downstream of type I IFN receptors such as
IRF9 results in the transcription of interferon stimulated genes (ISGs). The products of these ISGs play multifaceted roles: some can directly
restrict processes such as viral replication and egress from the host cell, but some ISGs such as IFITM3 may also influence cytokine production
in haematopoietic cells such as DCs. The cytokines produced early in infection also regulate the differentiation of T cells, with the balance
between different T-cell subsets demonstrated to alter disease progression. Genes involved in these key processes, where specific genetic
variants have been identified as associated with altering host inflammatory responses to IAV, RSV or SARS-CoVs, are shown. These genetic
variants are further described in Table 1. Created with BioRender.com.
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Table 1. Genetics variants contributing to respiratory disease.
Gene Polymorphism Effect on protein/function Disease susceptibility virus association, and
related host process presented in Fig. 1
(initiation/disease progression)
Cytokines, chemokines and receptors
CCR5 CCR5-Δ32 32 bp deletion in CCR5 coding region resulting in
partially reduced receptor expression
↑Influenza A121
Enhancement of cytokines and ISG induction by
recruited cells
IL1A rs17561 G > T Ser114Ala Unknown ↑Influenza A119
Production of cytokines and chemokines
IL1B rs1143627 T > C Possible increased IL1B expression associated with T
allele; rs1143627 located on TATA box of IL1B
promoter region, may affect TF binding
↑Influenza A119
Production of cytokines and chemokines
TNF rs361525 (TNF −238 A allele) G > A Decreased TNF transcripts ↑Influenza A118
Production of cytokines and chemokines
Enhancement of cytokines and ISG induction by
recruited cells
IL4 rs2243250 (IL4 −589T allele) C > T Increased IL4 transcripts ↑RSV (embedded within common IL4
haplotype defined at five loci)127
T-cell activation
Effector T-cell response
IL8 IL8 haplotype:
(−251A/+396G/+781T/
+1238delA/+1633T/
+2767T)
Increased IL8 transcripts ↑RSV130
Production of cytokines and chemokines
Enhancement of cytokines and ISG induction by
recruited cells
IL10 rs1800872 (−592 C/A allele) C > A Currently not clear whether the C or A allele is
associated with higher IL10 expression
↓RSV with heterozygosity at this allele137
↑RSV− 592 C allele in children ≤6 months of
age137
Enhancement of cytokines and ISG induction by
recruited cells
T-cell activation
IL13 rs1881457 (−1512 C allele) A > C
rs1800925 (−1112 C/T allele) C > T
Unknown
Altered expression of IL13 and increased binding of
nuclear factors to IL13 promoter
↑RSV with −1512 C allele in the presence of
allele 50 Ile in IL4R (rs1801275)128
↑RSV128
T-cell activation
Effector T-cell response
IL6 rs1800795 (−174 G/C allele) G > C −174 CC low producer phenotype ↑RSV with CC allele132
Production of cytokines and chemokines
Enhancement of cytokines and ISG induction by
recruited cells
T-cell activation
IFNA5 rs10757212 C > T Unknown ↑RSV135
Production of cytokines and chemokines
RANTES rs2280788 (−28 G allele) C > G Possible enhanced promoter activity ↑SARS-CoV-1138
Production of cytokines and chemokines
IFNGR1 201-2 A > G Complete absence of IFN-γ responsiveness
observed with homozygosity. Mutation in splice site
at end of intron 2, in frame deletion of 34 amino
acids, generating a truncated protein of assumed
non-function.
↑RSV112
Enhancement of cytokines and ISG induction by
recruited cells
T-cell activation
Effector T-cell response
Pattern recognition receptors
TLR3 rs5743313 T > C Located in transmembrane signal transduction
domain; potentially linked to reduced signalling
↑Influenza A with CC and CT genotypes144,145
Detection of virus
DDX58 rs72710678 G > A Arg71His
rs138425677 C > T Pro885Ser
CARD domain; decreased recognition function of
RIG-I, impaired antiviral immune responses
RNA binding domain; decreased recognition
function of RIG-I, impaired antiviral immune
responses
↑Influenza A146
Detection of virus
TLR8 rs3761624 A > G Located in TLR8 promoter region. Increased TLR8
mRNA expression following acute and chronic DNA
damage stress in a p53RE SNP-dependent manner.
Minor G allele creates a CWWG core in the second
decamer of the p53RE within the TLR8 promoter.
The A allele in the rs3761624 variant disrupts the
CWWG core, reducing p53 binding
↑RSV with G allele148
Detection of virus
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TLR4 ectodomain, previously associated with TLR4 hypo-
responsiveness to lipopolysaccharide (LPS), were represented at
higher frequencies in children with symptomatic RSV disease.148
Polymorphisms in TLR2 and TLR9 have been associated with more
severe RSV-induced disease in children, although the mechanism
of these SNPs has not been defined.149 Thus, overall, SNPs
associated with increased and decreased PRR functionality
associate with severity of respiratory viral infections.
Transcription factors
Genetic variation in signalling molecules and TFs that act
downstream of PRRs may also influence virus-induced inflamma-
tory responses. Interferon regulatory factor 5 (IRF5) acts
downstream of TLR7 and, possibly, RIG-I sensing of IAV to induce
subsequent cytokine production.150 In humans, multiple SNPs
have been identified in the IRF5 gene and regulatory regions, with
some of these SNPs altering expression levels of IRF5,151 implying
that altered expression of TFs such as IRF5 could influence the
magnitude of host inflammatory responses. As IRF5 has been
implicated in other inflammatory conditions, such as systemic
lupus erythematosus and inflammatory bowel disease, there is
already interest in IRF5 as a therapeutic target in individuals with
altered IRF5 expression.152 IRF7 is known to act downstream of
various PRRs, initiating transcription of type I IFN genes.
Heterozygous null mutations in IRF7 can lead to life-threatening
IAV infection associated with significantly reduced type I and type
Table 1. continued
Gene Polymorphism Effect on protein/function Disease susceptibility virus association, and
related host process presented in Fig. 1
(initiation/disease progression)
TLR4 rs4986790 A > G/A > T Asp299Gly
rs4986791 C > T
Located in ectodomain of TLR4; hyper-responsive
LPS phenotype
Located in ectodomain of TLR4; hyper-responsive
LPS phenotype
↑RSV148
Detection of virus
TLR2 rs1898830 C > A
rs7656411 G > T
Intron variant
Downstream variant 500 kB
↑Bronchiolitis149
Detection of virus
TLR9 rs352162 C > T
rs187084 C > T
Unknown
Upstream variant 2 kB
↑Bronchiolitis149
Detection of virus
IFIH1 rs35732034 C > T (IFIH1-Δ14)
rs35337543 C > G (IFIH1-Δ8)
Minor allele T causes skipping of exon 14, resulting
in a frame shift and an early stop codon in exon 15.
IFIH1 protein lacks final 153 amino acids, including
the C-terminal regulatory domain (CTD), essential
for viral dsRNA binding
Minor allele G causes skipping of exon 8, removing
39 amino acids at the end of the helicase 1 domain
and in the linker part between helicase 1 and
helicase 2
Severe disruption of IFIH1 signalling function,
enzymatic activity, and protein stability in vitro
demonstrated for both IFIH1-Δ8 and IFIH1-Δ14
↑RSV8
Detection of virus
Transcription factors
IRF7 Two compound heterozygous IRF7
mutations—p.Phe410Val (F410V)
and p.Gln421X (Q421X)
F410V: missense substitution predicted to be
damaging
Q421X: nonsense mutation predicted to generate a
premature stop codon
Both alleles–lack of IRF7-dependent amplification of
type I and III IFN post-influenza exposure
↑Influenza153
Production of cytokines and chemokines
Enhancement of cytokines and ISG induction by
recruited cells
IRF9 991 G > A Mutation in final nucleotide of exon 7 disrupts the
essential splice site at the boundary of exon 7 and
intron 7, resulting in mRNAs lacking exon 7 and an
IRF9 protein probably lacking the IRF association
domain (IAD), where STAT proteins bind. Cells with
this mutation are impaired in ISG induction
↑Influenza154
IFN response and ISG induction
Enhancement of cytokines and ISG induction by
recruited cells
JUN rs11688 G > A Unknown; synonymous variant ↑RSV135
Production of cytokines and chemokines
VDR rs10735810 (also rs2228570) C > T
Thr1Met
Initiator codon variant, located at first start codon in
exon 2, changes the translation initiation site,
resulting in a truncated protein. Truncated protein
may have higher activity than the wild type protein
↑RSV135
Enhancement of cytokines and ISG induction by
recruited cells
Viral restriction factors
IFITM3 rs12252 T > C
rs34481144 C > T
Unknown; synonymous variant
Located in the promoter region of IFITM3,
repression of IFITM3 expression with A allele,
possibly through enhanced CTCF binding to IFITM3
promotor
↑Influenza162,163,166
↑SARS-CoV-2163
↑Influenza161
IFN response and ISG induction
Enhancement of cytokines and ISG induction by
recruited cells
↑= increased disease susceptibility/increased severity of symptoms; ↓= decreased disease susceptibility/decreased severity of symptoms
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III IFN production and increased viral replication.153 Polymorph-
isms in IRF7 have also been shown to alter the ability of
plasmacytoid DCs to produce IFN-α in response to HIV-1, so it is
not unreasonable to suggest these polymorphisms may also alter
IFN responses to respiratory viral infections and associated
pathogenesis. IRF9 is a key component of the ISG factor 3 trimer.
In a child homozygous for a loss-of-function mutation IRF9 allele
hospitalised for severe pulmonary influenza, the child’s cells were
shown to be unable to respond fully or effectively to type I IFN,
leading to a loss of viral control through the lack of ISG
activation.154 AP-1 combines with other TFs to activate transcrip-
tion of cytokines and type I IFN. The rs11688 SNP in JUN, which
encodes part of the AP-1 TF, associates with severe RSV-
bronchiolitis.135 In the same study, polymorphisms in vitamin D
receptor (VDR) gene, demonstrated to increase the transcriptional
activity of VDR, have been associated with the severity of RSV-
induced bronchiolitis. VDR has been associated with down-
regulating IL-12 and IFN-γ production.149
Viral restriction factors
Antiviral restriction factors constitute a first line of defence
against viral entry to cells, blocking viral replication and
propagation. Mx1 is an ISG and encodes a potent viral restriction
factor Mx1 in mice. Many inbred laboratory mice lack expression
of a functional Mx1 protein, which explains enhanced suscept-
ibility to influenza infection.22,155 In human populations, there
are allelic variants in MX1, and MXA, the GTPase encoded by
MX1, has been demonstrated to restrict IAV.156 However, none of
these variants have been linked to influenza susceptibility
currently.157 There is increasing evidence that some viral
restriction factors can also play additional, multifaceted roles,
for example, acting as innate sensors and triggering innate
immune responses.158 One important viral restriction factor is
the IFN-induced transmembrane protein 3 (IFITM3), which
restricts cell entry of mainly enveloped RNA viruses including
SARS-CoV and IAV.159,160 Several SNPs have been identified in
IFITM3, including rs34481144 within the promoter of IFITM3, with
the minor allele (A) of this SNP associated with severity of IAV
infection. The A allele of this SNP represses IFITM3 expression,
possibly through enhanced binding of CTCF to the IFITM3
promotor in this genotype.161 The CC genotype of the rs12252
SNP, located in exon 1 of IFITM3, has been associated with
severity of IAV infections by several groups.162,163 This associa-
tion was not observed in similar studies in European populations,
where the frequency of the CC genotype is very low,164,165
however, a recent meta-analysis confirmed the association
between influenza susceptibility and rs12252.166 As is likely the
case with other risk alleles, cumulative effects have been
observed for TLR3 and IFITM3 risk genotypes, suggesting a
combination of genetic factors may influence host outcome
post-influenza infection.145 Additionally, the rs12252 CC geno-
type has been shown to be associated with more severe
outcomes in SARS-CoV-2-infected Chinese patients, in an age-
dependent manner.167 The specific mechanism behind associa-
tions with the rs12252 SNP is currently unknown; initial
predictions that the CC genotype would result in a truncated
form of IFITM3 through alternative splicing have not been
confirmed in subsequent studies.168 More recently, IFITM3 has
been shown to play roles asides from direct viral restriction. In a
murine cytomegalovirus (MCMV) infection model, Ifitm3 acts to
limit MCMV-related pathogenesis, independently of viral replica-
tion, by limiting the production of pro-inflammatory cytokines,
particularly IL-6.169 In humans, severe IAV disease in individuals
with the CC genotype of the rs12252 SNP is associated with high
CCL2 levels that drive pathogenic monocyte responses20,163 and
hypercytokinemia characterised by elevated levels of cytokines
including IL-6 is associated with fatal H7N9 infection in
individuals with the rs12252 CC genotype.170
INDUCED PLURIPOTENT STEM CELLS (IPSCS) AS TOOLS FOR
STUDYING VIRAL INFLAMMATION
Investigation of respiratory viral infections has relied heavily on
murine models and human cell lines, with important contributions
of both of these systems to understanding disease pathogenesis.
The mouse collaborative cross, a genetically diverse murine panel
with up to eight functionally variant alleles at any given locus,
generated to try to recapitulate human allelic diversity, provides a
promising tool for addressing how genetic diversity can impact
infection outcomes. In challenges with IAV, this model replicates
human blood transcriptional responses to infection and has
identified several quantitative trait loci contributing to specific
host responses.171,172 Human association studies that have
identified polymorphisms in biologically plausible gene candi-
dates provide some insights into molecular genetic contribution
to pulmonary infections and disease severity; however, the
function of these SNPs needs to be further dissected,173 as
statistical association studies do not provide mechanisms, making
it difficult to establish causality between a candidate genotype
and a clinical phenotype. Understanding these mechanisms
requires detailed biochemical and immunological studies.174
Findings from mouse models do not always translate to human
disease, and most animal studies dissecting gene function have
relied on full gene knockouts, which, whilst elucidating the role of
that gene in response to pathogens such as influenza, do not
provide information about differential responses associated with
allelic variation.175 Also, importantly, there is a greater level of
redundancy in human immunity in comparison to inbred mouse
lines, which means that phenotypes observed in mice are not
always replicated in human studies.106 For studying human
cellular phenotype, the reductionist approach of using cell lines
is often applied, but these cells lack some of the morphological
characteristics of primary human cells, and do not allow the
incorporation of human genotype. Therefore, there is a need for
development of models enabling the study of causative mechan-
isms for effects of specific gene variants, which are currently
lacking.124
Takahashi et al.176 demonstrated that pluripotent stem cells
could be generated from adult somatic cells by transduction with
four TFs, providing an exciting opportunity for disease modelling
in multiple cell and tissue types. iPSCs allow for the recapitulation
of human ‘disease in a dish’ by facilitating the growth of unlimited
quantities of a specific individual’s cells and the differentiation of
these cells down multiple cellular lineages.177 Due to limited
techniques to combine human genetics and the mechanisms of
human cell biology, iPSCs fill a significant research gap, allowing
for exploration of the effects of human genotype on cell
phenotype.178 Thus far, the use of iPSCs in facilitating host-viral
research is still quite limited. However, some key studies have
highlighted the potential of these systems to further dissect
pathways regulating immune responses to viruses, and explore
how differences in genetics may perturb these pathways.
In a study exploring genetic causes of severe influenza,
heterozygous null mutations were identified in IRF7 in a child
suffering from life-threatening influenza. iPSCs generated from
this patient and differentiated into pulmonary epithelial cells
produced reduced type I IFN and allowed increased influenza virus
replication.153 Furthermore, patient-derived iPSCs were used to
demonstrate that impaired TLR3- and UNC-93B-dependent IFN-α/
β intrinsic immunity to HSV-1 in the CNS may underlie the
pathogenesis of HSV-1 encephalitis in children with TLR3-pathway
deficiencies.179 We have also demonstrated the use of iPSC-
derived dendritic cells (iPS-DCs) and iPSC-derived macrophages
(iPSDMs) to investigate the role of IRF5 in regulating pro-
inflammatory cytokine production after exposure of iPS-DCs and
iPSDMs to IAV.150
Identification of more genetic variants that are associated with
variations in viral-induced inflammatory responses will help to
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determine novel gene associations that will advance the under-
standing of the molecular pathways involved in pathogenesis of
specific viral diseases. Furthermore, in the last decade GWAS
identified multiple genetic variants that contribute to various
phenotypes; iPSCs are ideally placed to dissect how these variants
contribute to the phenotypes described. With recently developed
technologies such as CRISPR/Cas9, which allow for precision gene
editing to generate, for example, isogenic control lines differing in
just one SNP location,180–182 the mechanistic implications of allelic
variation in genes of interest can really begin to be probed.
Furthermore, the development of large iPSC banks means that in
the future experiments can be conducted on a population level
scale.178 iPSC technology opens up essential new avenues for
exploring the contribution of genetics to infectious disease
susceptibility, and may allow for better preparation in the future
for emerging viral threats.
CONCLUSIONS
It is clear that inflammation plays a role in the pathology of various
respiratory diseases. Modulating this inflammation as a therapeu-
tic strategy remains challenging, as a delicate balance between
protective immunity and excessive inflammation is a key.
However, therapies targeting the host immune system are being
trialled for different viral infections, and are attractive therapeutic
prospects due to issues with increasing viral resistance to
traditional antiviral therapies and the constant pressures on
vaccine development due to emergence of novel viral strains in
human populations. Furthermore, due to cross-over between the
host pathways for viral-induced cytokine regulation for different
viral pathogens, it is possible that host immunomodulatory
therapies could be rapidly re-purposed in the advent of a
pandemic. Therefore, enhanced understanding of these pathways,
and how over-activation post-infection affects host survival, may
be crucial.
Understanding the underlying genetics of specific individuals,
which may alter that individual’s propensity to experience
overexuberant inflammatory responses after viral infection, could
be very important for helping to design better immune
modulators. Critically, such insight may be used to potentially
stratify patients into high risk categories and tailor specific anti-
inflammatory treatments based on understanding what immune
responses are likely affected in these individuals. During the
current COVID-19 pandemic, it is essential that we obtain as much
information as possible regarding host factors that influence virus-
induced inflammation, both to inform current clinical manage-
ment of SARS-CoV-2 infection and to identify host genetic variants
that, either in isolation or combination, alter inflammatory
responses to other respiratory viral infections circulating in the
human population presently, and in the future.
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